Elucidata, which makes software to support drug discovery, recently released a metabolomics analysis platform that includes machine learning technology.
The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
Genome-wide association study hits can uncover potential therapies for conditions like inflammatory bowel disease, a Biology of Genomes speaker said.
With the Series B funding, Sytenkabio will consolidate its headquarters in Seoul, validate its technology, and look to expand into international markets.
Datavant, a fledgling spinoff from Roivant Sciences, is trying to break down information silos that often lead to poorly designed clinical trials.
Envisagenics, which was spun out of Cold Spring Harbor Laboratory, has developed a platform to help drug companies address RNA splicing errors.
Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.
Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."
TwoXar will work with Stanford's Asian Liver Center to identify and validate computationally-derived drug candidates that target hepatocellular carcinomas.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.